Large prospective trials on autoHCT consolidation as part of PTCL frontline therapy
| . | GLA/LYSA AATT10,11 (autoHCT arm only) . | Nordic8 . | German9 . |
|---|---|---|---|
| Study type | RCT (auto vs allo) | Phase 2, prospective | Phase 2, prospective |
| Eligibility | NOS, AITL, ALCL ALK−, EATL, HSTL, SPPTCL | NOS, AITL, ALCL ALK−, EATL, HSTL, ENKTCL | NOS, AITL, ALCL ALK−, EATL, HSTL, ENKTCL |
| 18-60 y | 18-67 y | 18-65 y | |
| N (% AITL+ALCL+NOS) | 54 (78%) | 160 (77%) | 111 (85%) |
| AITL | 31% | 19% | 33% |
| ALCL ALK− | 17% | 19% | 14% |
| PTCL-NOS | 30% | 39% | 38% |
| Period | 2011-2014 | 2001-2007 | 2001-2010 |
| Age (years; median [range]) | 50 (28-60) | 57 (22-67) | 49 (23-66) |
| PS > 1 (ECOG) | 20% | 29% | NA |
| aaIPI high/high-intermediate | 56% | NA | 58% |
| LDH > N | 61% | 62% | 58% |
| Proceeded to HCT | 63% | 72% | 68% |
| High-dose regimen | BEAM | BEAM | TBI/CY |
| Progression-free survival | |||
| 3 y | 39% | 48% | 49%b |
| Long-term | 35% (7 y) | 44% (5 y) | 30% (7 y)b |
| Overall survival | |||
| 3 y | 70% | 56% | 56%b |
| Long-term | 61% (7 y) | 51% (5 y) | 39% (7 y)b |
| Adverse factors | PFS: LDH > Na | OS, PFS: non-ALCL, age, PS >1 | OS: aaIPI high/high-intermediate |
| Follow-up (mo) | 84 (0-109) | 61 (26-96) | 59 (1-107) |
| . | GLA/LYSA AATT10,11 (autoHCT arm only) . | Nordic8 . | German9 . |
|---|---|---|---|
| Study type | RCT (auto vs allo) | Phase 2, prospective | Phase 2, prospective |
| Eligibility | NOS, AITL, ALCL ALK−, EATL, HSTL, SPPTCL | NOS, AITL, ALCL ALK−, EATL, HSTL, ENKTCL | NOS, AITL, ALCL ALK−, EATL, HSTL, ENKTCL |
| 18-60 y | 18-67 y | 18-65 y | |
| N (% AITL+ALCL+NOS) | 54 (78%) | 160 (77%) | 111 (85%) |
| AITL | 31% | 19% | 33% |
| ALCL ALK− | 17% | 19% | 14% |
| PTCL-NOS | 30% | 39% | 38% |
| Period | 2011-2014 | 2001-2007 | 2001-2010 |
| Age (years; median [range]) | 50 (28-60) | 57 (22-67) | 49 (23-66) |
| PS > 1 (ECOG) | 20% | 29% | NA |
| aaIPI high/high-intermediate | 56% | NA | 58% |
| LDH > N | 61% | 62% | 58% |
| Proceeded to HCT | 63% | 72% | 68% |
| High-dose regimen | BEAM | BEAM | TBI/CY |
| Progression-free survival | |||
| 3 y | 39% | 48% | 49%b |
| Long-term | 35% (7 y) | 44% (5 y) | 30% (7 y)b |
| Overall survival | |||
| 3 y | 70% | 56% | 56%b |
| Long-term | 61% (7 y) | 51% (5 y) | 39% (7 y)b |
| Adverse factors | PFS: LDH > Na | OS, PFS: non-ALCL, age, PS >1 | OS: aaIPI high/high-intermediate |
| Follow-up (mo) | 84 (0-109) | 61 (26-96) | 59 (1-107) |
Pooled autoHCT and alloHCT.
Estimated from published survival plots.
ALK−, ALK-negative; CY, cyclophosphamide; EATL, enteropathy-associated T-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; ENKTCL, extranodal NK/T-cell lymphoma; NA, not available; RCT, randomized controlled trial; SPPTCL, subcutaneous panniculitis-like PTCL.